BioXcel Therapeutics
(NASDAQ) BTAI
BioXcel Therapeutics Financials at a Glance
Market Cap
$30.68M
Revenue (TTM)
$642.00K
Net Income (TTM)
$69.90M
EPS (TTM)
$-7.15
P/E Ratio
-0.13
Dividend
$0.00
Beta (Volatility)
1.54 (High)
Dividend
$0.00
Beta (Volatility)
1.54 (High)
Price
$1.25
Volume
38,926
Open
$1.37
Price
$1.25
Volume
38,926
Open
$1.37
Previous Close
$1.25
Daily Range
$1.25 - $1.37
52-Week Range
$1.17 - $8.08
Dividend
$0.00
Beta (Volatility)
1.54 (High)
Price
$1.25
Volume
38,926
Open
$1.37
Previous Close
$1.25
Daily Range
$1.25 - $1.37
52-Week Range
$1.17 - $8.08
BTAI News
BTAI: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout BioXcel Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
29
CEO
Vimal D. Mehta, PhD
Website
www.bioxceltherapeutics.comHeadquarters
New Haven, CT 06511, US
BTAI Financials
Key Financial Metrics (TTM)
Gross Margin
51%
Operating Margin
-78%
Net Income Margin
-109%
Return on Equity
0%
Return on Capital
6%
Return on Assets
-2%
Earnings Yield
-7.69%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$30.68M
Shares Outstanding
24.35M
Volume
38.93K
Short Interest
0.00%
Avg. Volume
1.37M
Financials (TTM)
Gross Profit
$178.00K
Operating Income
$49.70M
EBITDA
$50.46M
Operating Cash Flow
$57.62M
Capital Expenditure
$0.00
Free Cash Flow
$57.62M
Cash & ST Invst.
$28.41M
Total Debt
$109.59M
BioXcel Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$256.00K
-30.1%
Gross Profit
$150.00K
+132.2%
Gross Margin
58.59%
N/A
Market Cap
$30.68M
N/A
Market Cap/Employee
$829.21K
N/A
Employees
37
N/A
Net Income
$12.54M
-15.5%
EBITDA
$10.10M
-49.6%
Quarterly Fundamentals
Net Cash
$81.18M
-11.1%
Accounts Receivable
$233.00K
+77.9%
Inventory
$722.00K
+6.3%
Long Term Debt
$84.66M
-17.5%
Short Term Debt
$24.93M
+6566.0%
Return on Assets
-1.56%
N/A
Return on Invested Capital
5.56%
N/A
Free Cash Flow
$14.21M
+4.0%
Operating Cash Flow
$14.21M
+4.0%